1-4 of 4
Dennis F Moore, Jr., MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System Lymphoma (PCNSL)[E1F05]

Lode J. Swinnen, MBChB, Anne O'Neill, Philip H Imus, MD, Sachin Gujar, MBBS, MD, David Schiff, MD, Lawrence Kleinberg, Ranjana Advani, Erin Dunbar, MD, Dennis F. Moore, Jr., MD, Stuart Grossman, MD
Journal: Blood
Blood (2015) 126 (23): 1530.
https://doi.org/10.1182/blood.V126.23.1530.1530
Published: 2015
Journal Articles

Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997

Mitchell R Smith, MD, PhD, Donna Neuberg, ScD, Ian W. Flinn, MD, PhD, Michael R. Grever, M.D., John M. Bennett, MD, Gordon Dewald, Elisabeth M Paietta, PhD, Mark R. Litzow, MD, Jacob M. Rowe, David Lucas, PhD, Shinichi Kitada, Ph.D., Diane F. Jelinek, PhD, John G. Gribben, MD, DSc, John C. Byrd, MD, John C. Reed, MD, PhD, Mohamad A. Hussein, M.D., Frederick R. Appelbaum, MD, Richard A. Larson, MD, Dennis F Moore, Jr, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2010) 116 (21): 924.
https://doi.org/10.1182/blood.V116.21.924.924
Published: 2010
Journal Articles

A Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week Epoetin Alfa and Every-3-Week Darbepoetin Alfa: A Study of the Mayo Clinic Cancer Research Consortium (MCCRC).

David P Steensma, MD, Shaker R. Dakhil, MD, Paul J Novotny, MS, Jeff A Sloan, PhD, David B Johnson, MD, Daniel M Anderson, MD, Bassam I Mattar, MD, Dennis F Moore, Jr., MD, Daniel Nikcevich, MD, PhD, Charles L Loprinzi, MD
Journal: Blood
Blood (2009) 114 (22): 3008.
https://doi.org/10.1182/blood.V114.22.3008.3008
Published: 2009
Journal Articles

Fludarabine and Cyclophosphamide Produces a Higher Complete Response Rate and More Durable Remissions than Fludarabine in Patients with Previously Untreated CLL: Intergroup Trial E2997.

Ian W. Flinn, MD, PhD, Elizabeth Kumm, MS, Michael R. Grever, MD, Donna Neuberg, ScD, Gordon W. Dewald, PhD, John M. Bennett, MD, Elisabeth M. Paietta, PhD, Mohamad A. Hussein, MD, Dennis F. Moore, Jr., MD, Martin S. Tallman, MD
Journal: Blood
Blood (2004) 104 (11): 475.
https://doi.org/10.1182/blood.V104.11.475.475
Published: 2004